Delegates’ experience

José María Fernández Sousa-Faro
President of Pharmamar

What are your expectations and goals for attending BIOSPAIN?

This meeting, that is organised by the Spanish Bioindustry Association (ASEBIO), gives us the opportunity to get acquainted with the innovation taking place within the health sector, and above all, within the field of new oncological therapies, pharmacology and the public policies’ approach to innovation or new drug diagnostic methodology.

We also believe that ASEBIO is making a great effort in offering visibility to Spanish innovation community, underlining the work done by national companies in R&D. In this context, the importance of giving voice to the patients associations is also highlighted , trying to identify their necessities and reaching co-operation agreements that allow a progression In the development of novel treatments.

Antonio Gomez 
Spain New Ventures Lead, Johnson & Johnson Innovation

What are your expectations and goals for attending BIOSPAIN?

Janssen and Johnson & Johnson seek to positively impact human health through innovation. We firmly believe that, in the current world, collaboration with external partners is a crucial way to achieve this goal. Since the creation of Johnson & Johnson Innovation in 2013 we have been looking for opportunities within our areas of interest which can be developed into new solutions for patients. But we don´t want to be simple spectators. Our ambition is to become an active part of the innovation ecosystem in Biomedicine. In Spain, we have already taken a major step forward with the I2D2 project, where we want to help mature promising science which is normally considered too early for investment by corporations or VC groups. With our engagement in Biospain we want to reach out to the Biotech community in the country with three main objectives: following up the projects that we already know, letting the ecosystem know what we are doing and what opportunities we can offer and, last but not least, getting to know new companies now working in projects with the potential to become the therapeutics of the future.

What does Biospain offers J&J versus other international events?

Being the reference event for the sector,  It is the place to get a comprehensive view of the Biotech ecosystem in the country. Not to forget also the excellent organization and outstanding places where it is set.

Why do you think a professional cannot miss this event?

Biospain brings together all the stakeholders in the Biotech sector in Spain, complemented with major international actors. You get immersed in this field which is now just blossoming, having its foundation on world-level science and surrounded by an increasingly more mature environment. If you want to dig into the Spanish Biotech ecosystem Biospain is the place to be.

Andres Fernandez 
Ferrer Advanced Therapeutics, Director

Have you attended BIOSPAIN in the past? If so, what was your experience?

I have regularly attended previous editions.  BIOSPAIN is a great opportunity to communicate and share science and build business opportunities.

What does Biospain offers Ferrer versus other international events?

Biotech in Spain has achieved a high degree of maturation. BIOSPAIN is a unique event to check novelties and opportunities both in the academic and start-up communities. In addition to an almost complete view of the Spanish landscape, there is a high and even increasing penetration of European and LatAm delegates.

For someone who is thinking to attend BIOSPAIN for the first time, what would you tell her/him?

The conference is always exciting. You will enjoy so much meeting new colleagues at the venue.  The organization is particularly successful combining outstanding conferences sessions,  well-designed face-to-face meetings and relaxing networking events in the evening.

Susana DeAntonio 
Director – Spain Representative Euronext

What are your expectations and goals for attending BIOSPAIN?

At a certain stage of development, companies may consider opening up their capital to a wider range of shareholders as the next major milestone. The stock markets are an effective way to have access to a wide range of funding options to grow your business.
Euronext is the leading pan-European exchange, spanning Belgium, France, The Netherlands, Portugal and the UK. With over 1 300 issuers worth €3.5 trillion in market capitalization and a traded value of €2.2 trillion since January 2016, Euronext gathers the biggest liquidity pool in Europe.
In order to help European Tech SMEs take the next step, Euronext decided to go beyond its domestic markets and deploy, hand-in-hand with players of the local ecosystems, a tailor-made offer in Switzerland, Germany, Italy and Spain.

​Our goal is meet innovative scale-up in the life sciences industries to introduce them to Euronext and how they can finance their growth via Capital Markets. Euronext is the leading listing venue in the world for Medtech and second – after the US – for Biotech.

What does Biospain offers Euronext versus other international events?

Biospain is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings (+3.000) and companies participating (+800). Recent record-breaking years have demonstrated that Europe is becoming a worldly hotbed of real pioneering innovations. Indeed, thousands of Tech SMEs are demonstrating remarkable performances. Biotech and Medtech are some of our main focuses with 56 and 37 companies currently listed on Euronext markets, respectively, out of 347 Tech Listed SMEs.

Why do you think a professional cannot miss this event?

Biospain is a unique opportunity to meet face to face with the majority of biotech industry and international companies/institutions from around the world in one of its largest international events

Joan Puig de Dou
C.E.O. Kymos Pharma Services

What are your expectations and goals for attending BIOSPAIN?

Our main goal is strengthening KYMOS as a reference European CRO for biologics. KYMOS has developed a relevant know-how in biologics and specifically in biosimilars in CMC and bioanalysis fields with laboratories certified in GMP and GLP and inspected by EMA and FDA regulatory bodies.

What does Biospain offers Euronext versus other international events?

Biospain offers us an international partnering event focused in Southern European companies and markets. This give us more visibility than worldwide events, since Kymos has a stronger presence in countries such as Spain, France, Italy and Portugal, despite having very important references everywhere, but specially in Asia.

Why do you think a professional cannot miss this event?

An event like this allows to a pharmaceutical industry professional to concentrate many meetings in a short period of time, extending his/her professional network with relevant people.

Javier Urzay
Deputy Director General Farmaindustria

What are your expectations and goals for attending BIOSPAIN?

The pharmaceutical industry is a leader in industrial R&D, with more than 20 percent of total investment in Spain. Of the 1,147 million euros invested in 2017, almost half corresponds to collaboration contracts with hospitals and research centers, showing the growing importance of the model of open innovation and public-private collaboration. Along this line, and in the framework of the Technological Platform of Innovative Medicines, which has the support of the Ministry of Science, Innovation and Universities, in 2011 Farmaindustria started the FARMA-BIOTECH Programme, with the aim of promoting collaboration amongst the industry and biomedical researchers, looking for projects with real capacity to offer a high innovative potential at the time of entering the programme and with reasonable expectations of achieving commercial success in the medium term. In the session organised in BIOSPAIN, we will discuss some of the obstacles that determine the ability of the Spanish science and technology system to transfer efficient results to the industry and finally to the market. Also, pharmaceutical companies, national and international, increasingly involved in public-private collaboration programs, will present initiatives in this field.

What does Biospain offers Euronext versus other international events?

BIOSPAIN responds to the context of open innovation in which the Pharma-Biotech Cooperation Programme is developed. In the session sponsored by the Association, relevant personalities of the biopharmaceutical industry, research centers, financing entities and venture capital will participate, as well as representatives of networks and mechanisms to support technology transfer.

Why do you think a professional cannot miss this event?

In this session, the role of existing mechanisms to improve fluency and effectiveness among the different stakeholders within the system will be assessed and some examples will be offered that are working, both from the public and private sectors. In this way, there will be an efficient exchange of information and personal knowledge amongst the different stakeholders involved. In short, it is a good opportunity for different professionals to learn about opportunities to take advantage of Spanish biomedical research in concrete economic terms.

Josep Ll. Sanfeliu
Managing Partner – Co-Founder

What are your expectations and goals for attending BIOSPAIN?

We are attending BIOSPAIN with the goal of connecting with the biotech and medtech industry gathering at the event: entrepeneurs, key opinion leaders, industry players and in general with all those participating and leading the biotech and medtech ecosystem in the South of Europe. Asabys works closely with entrepreneurs in the world of life sciences and we expect all the industry leaders in Spain and some of the European players to be part of this meeting. We are sure, Asabys Patners will have the opportunity in BIOSPAIN to meet, greet and strengthen our ties with those who want to build life sciences disruptive companies with the aim of transforming people’s lives providing disruptive solutions to current social health challenges.

What does Biospain offers Euronext versus other international events?

Biospain is the largest biotech and medtech event organized in the South of Europe and one of the largest of its type in Europe and in the US. The level of maturity of the Spanish biotech/medtech and health innovation industry shows a very dynamic sector in a country which is now flourishing in a strong and an sustainable way after several recent years of company creation activity, international venture capital funding and also corporate funding and mergers and acquisitions. Probably compared with other mature markets in Europe, attending BIOSPAIN can help participate and be part directly or indirectly in probably the most and recently dynamic corporate, start-up and venture capital biotech and medtech market in the continent.

Why do you think a professional cannot miss this event?

After more than 15 years of growth of the sector in which we have seen the raise and fall of many, the consolidation of the industry, the arrival of international players both corporate and financial, successful stories both for entrepreneurs and investors, etc. is precisely why today is the right time to be part of BIOSPAIN.

María Dolores Fernandez Jimenez
Head of Market Access and Policy in Amgen Spain

What are your expectations and goals for attending BIOSPAIN?

My goal is to increase the biotech knowledge and visibility, to have the opportunity to contact with opinion leaders in biotech and share ideas with them, it is a good opportunity to increase the networking among biotech professionals.

What does Biospain offers Euronext versus other international events?

The opportunity to be involved in the agenda and propose Key Opinion Leaders as speakers in symposiums, in order to increase the scientific level of seminars in the congress.

Why do you think a professional cannot miss this event?

Because is an opportunity to get the most relevant information about biotech innovation and share knowledge and best practices with relevant experts in biotech environment.

Alberto Borrego Díez
Partner at everis, an NTT DATA company

What are your expectations and goals for attending BIOSPAIN?

Among the global trends that define today’s world there are two with an special transformation potential to address the challenges that we are facing as a society, the biotechnological revolution and the digital revolution.

Everis, an NTTD company, as a global organization is committed with the adoption of digital technologies and how these technologies can help us to change and evolve. We think that disruptive trends can arise from the appropriate interaction between the biotech and digital worlds. In Biospain, as the largest event of its kind in Europe, we are seeking for opportunities to enable these interactions.

What does Biospain offers Euronext versus other international events?

Biospain offers us an unparallel forum to access the biotech ecosystem, from manufacturing or finance to precision medicine innovation. Due to this large scope, it is a very good opportunity for us to frame digital transformation in the biotech world. Spain, is a stronghold for the biotech industry; but it is also the source of activity and knowledge of everis in the healthcare sector. For us, it is a very good location to seek for synergies.

Why do you think a professional cannot miss this event?

Attending Biospain brings professionals the opportunity of a full approach to the state of art of biotech industry, in Spain, but also at an international level.

Furthermore, it provides access to  partners, financers or suppliers of biotech solutions. All in one shot.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here, or follow this link for more information about cookies.

ACEPTAR
Aviso de cookies